Last month's question:
In a study assessing two different antiplatelet agents in the prevention of stroke, 10,000 subjects were randomised to receive either the standard therapy or the new therapy.
Over the study period of five years, the side effect of major gastrointestinal (GI) bleeding was 3% in the standard therapy group compared with 2% in the new therapy group.
Which of the following is the absolute risk reduction associated with the new therapy in major GI bleeds?
We are not told whether there is a significant difference between the two groups yet in the standard antiplatelet therapy group there is a risk of GI bleed of 3% versus 2% with the new therapy.
This is a 1% absolute risk reduction and a 33% relative risk reduction (1/3).
The number of people that would need to be treated with the new drug to avert the major effect of bleeding would be 100.
Take part in our monthly quiz to give yourself a chance of winning one of the following great prizes:
Which of the following pharmacological agents acts through the opening of potassium channels?
Please can you confirm which stage you are in your medical career? (Please only enter your stage in your medical career if you agree that it may be used for promotional activities from onExamination)